Tags

Type your tag names separated by a space and hit enter

Emerging migraine treatments and drug targets.
Trends Pharmacol Sci 2011; 32(6):352-9TP

Abstract

Migraine has a 1-year prevalence of 10% and high socioeconomic costs. Despite recent drug developments, there is a huge unmet need for better pharmacotherapy. In this review we discuss promising anti-migraine strategies such as calcitonin gene-related peptide (CGRP) receptor antagonists and 5-hydroxytrypamine (5-HT)(1F) receptor agonists, which are in late-stage development. Nitric oxide antagonists are also in development. New forms of administration of sumatriptan might improve efficacy and reduce side effects. Botulinum toxin A has recently been approved for the prophylaxis of chronic migraine. Tonabersat, a cortical spreading depression inhibitor, has shown efficacy in the prophylaxis of migraine with aura. Several new drug targets such as nitric oxide synthase, the 5-HT(1D) receptor, the prostanoid receptors EP(2) and EP(4), and the pituitary adenylate cyclase receptor PAC1 await development. The greatest need is for new prophylactic drugs, and it seems likely that such compounds will be developed in the coming decade.

Authors+Show Affiliations

Danish Headache Center & Department of Neurology, Glostrup Hospital, Faculty of Health Sciences, University of Copenhagen, Ndr. Ringvej 57, DK-2600 Glostrup, Denmark. jeol@glo.regionh.dkNo affiliation info available

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't
Review

Language

eng

PubMed ID

21459461

Citation

Olesen, Jes, and Messoud Ashina. "Emerging Migraine Treatments and Drug Targets." Trends in Pharmacological Sciences, vol. 32, no. 6, 2011, pp. 352-9.
Olesen J, Ashina M. Emerging migraine treatments and drug targets. Trends Pharmacol Sci. 2011;32(6):352-9.
Olesen, J., & Ashina, M. (2011). Emerging migraine treatments and drug targets. Trends in Pharmacological Sciences, 32(6), pp. 352-9. doi:10.1016/j.tips.2011.02.016.
Olesen J, Ashina M. Emerging Migraine Treatments and Drug Targets. Trends Pharmacol Sci. 2011;32(6):352-9. PubMed PMID: 21459461.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Emerging migraine treatments and drug targets. AU - Olesen,Jes, AU - Ashina,Messoud, Y1 - 2011/04/02/ PY - 2010/12/17/received PY - 2011/02/24/revised PY - 2011/02/24/accepted PY - 2011/4/5/entrez PY - 2011/4/5/pubmed PY - 2011/10/1/medline SP - 352 EP - 9 JF - Trends in pharmacological sciences JO - Trends Pharmacol. Sci. VL - 32 IS - 6 N2 - Migraine has a 1-year prevalence of 10% and high socioeconomic costs. Despite recent drug developments, there is a huge unmet need for better pharmacotherapy. In this review we discuss promising anti-migraine strategies such as calcitonin gene-related peptide (CGRP) receptor antagonists and 5-hydroxytrypamine (5-HT)(1F) receptor agonists, which are in late-stage development. Nitric oxide antagonists are also in development. New forms of administration of sumatriptan might improve efficacy and reduce side effects. Botulinum toxin A has recently been approved for the prophylaxis of chronic migraine. Tonabersat, a cortical spreading depression inhibitor, has shown efficacy in the prophylaxis of migraine with aura. Several new drug targets such as nitric oxide synthase, the 5-HT(1D) receptor, the prostanoid receptors EP(2) and EP(4), and the pituitary adenylate cyclase receptor PAC1 await development. The greatest need is for new prophylactic drugs, and it seems likely that such compounds will be developed in the coming decade. SN - 1873-3735 UR - https://www.unboundmedicine.com/medline/citation/21459461/Emerging_migraine_treatments_and_drug_targets_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0165-6147(11)00040-X DB - PRIME DP - Unbound Medicine ER -